Health Care Equipment

Sanyou Medical

Sanyou Medical released FY2026 Q1 earnings on April 27 After-Market (BJT), actual revenue CNY 123.57 M, actual EPS CNY 0.02

Sanyou Medical to Release FY2026 Q1 Earnings on April 28 After-Market (BJT)

Sanyou Medical to Release FY2025 Annual Earnings on April 28 During-Market (BJT), Forecast Revenue CNY 545 M, EPS CNY 0.25

Sanyou Medical released FY2025 Q4 earnings on February 26 During-Market (BJT), actual revenue CNY 151.33 M, actual EPS CNY 0.0036

Sanyou Medical released FY2025 earnings during market hours on February 26 (BJT), actual revenue CNY 542.79 M (forecast CNY 545 M), actual EPS CNY 0.19 (forecast CNY 0.25)

Sanyou Medical released FY2025 9 Months Earnings on October 27 After-Market (BJT), with actual revenue of CNY 391.47 M and EPS of CNY 0.1891

Sanyou Medical released FY2025 Q3 earnings on October 27 After-Market (BJT), actual revenue CNY 141.71 M, actual EPS CNY 0.081

Sanyou Medical to Release FY2025 Q3 Earnings on October 28 After-Market BJT

Sanyou Medical released FY2025 Q2 earnings on August 25 After-Market (BJT), actual revenue CNY 133.33 M, actual EPS CNY 0.0664

Sanyou Medical released FY2025 Semi-Annual earnings on August 25 After-Market (BJT), actual revenue CNY 249.76 M, actual EPS CNY 0.11

Sanyou Medical to Release FY2025 Semi-Annual Earnings on August 26, 2025 (BJT)

Implant SA's JAZZ Series Obtains CFDA Approval to Enter Chinese Market

Sanyou Medical Obtains Registration Certificate for Spinal Fixation Connector System

David Fan Executives of Sanyou Medical Reduce Shares via Block Trades

Sanyou Medical Receives Government Subsidy of 6.2286 Million Yuan

Director and Senior Executive of Sanyou Medical Plans to Reduce Shares

Subsidiary of Sanyou Medical Passes Special Review for Innovative Medical Device

Sanyou Medical Joins Forces with CGBio to Set Up Litian Biotech

Sanyou Medical Reports Declining Profits in 2024

Sanyou Medical released FY2025 Q1 earnings on April 28 During-Market (BJT), actual revenue CNY 116.43 M, actual EPS CNY 0.0417

688085

On April 15, 2026, in Shanghai, it was reported that the efficiency of early-stage molecule discovery is crucial for success in innovative drug R&D, including antibodies, peptides, and novel binding proteins. This discovery process plays a vital role in determining the outcome of projects. The importance of this phase is evident in the highly competitive landscape where the speed at which molecules are identified can make or break a project. Traditional methods...

Unusual Whales

Clicklinks | 14-Day Candidate Antibody Discovery - Sanyou AI-STAL 2.0 Defines the Era of Ultimate Speed in Drug Molecule Discovery

603259

02359

600276

000963

As of October 28, over 280 listed pharmaceutical and biotechnology companies, including Hengrui Pharma, HUADONG MEDICINE, WuXi AppTec, and Sanyou Medical, have disclosed their Q3 2025 reports, with many companies presenting impressive "report cards." Several pharmaceutical companies have achieved double growth in revenue and profit through the advancement of their R&D pipelines and the launch of innovative drugs, while breakthroughs in overseas business have injected new momentum into their performance. The industry as a whole is showing a positive development trend of "innovation as the foundation and expanding overseas." (Shanghai Securities Journal)

Wallstreetcn

WuXi AppTec

WUXI APPTEC

Hengrui Pharma

HUADONG MEDICINE

Innovation + Going Global, Highlights of Biopharmaceutical Companies' Q3 Reports

Shanghai Sanyou Medical Devices Co., Ltd. announced that it recently received a government subsidy of 1.405 million yuan, accounting for 12.25% of the audited net profit attributable to shareholders of the listed company for the year 2024. This subsidy is a government grant related to income, and the specific accounting treatment and its impact on the company's annual profit and loss will be subject to the confirmation results of the auditing agency. The company's board of directors reminds investors to pay attention to investment risks

Zhitong

Shanghai Sanyou Medical received a government subsidy of 1.405 million, accounting for 12.25% of last year's net profit

According to the Zhitong Finance APP, Sanyou Medical announced that the company has reviewed and approved the proposal on granting restricted stocks to the incentive objects of the 2025 restricted stock incentive plan, determining September 26, 2025, as the grant date, and granting 4.782 million shares of restricted stock at a grant price of 11.12 yuan per share to 55 eligible incentive objects

Sanyou Medical grants 4.782 million restricted shares to 55 incentive recipients

According to the Zhitong Finance APP, Sanyou Medical disclosed the pricing situation for the inquiry transfer by shareholders. Based on the inquiry subscription situation on September 23, 2025, the preliminary determined price for this inquiry transfer is RMB 18.11 per share. The shares intended for transfer in this inquiry have been fully subscribed, and the preliminary determined transferees are six institutional investors, with a total number of shares to be transferred amounting to 6.66925 million shares

Sanyou Medical: The preliminary inquiry transfer price is set at RMB 18.11 per share

According to the Zhitong Finance APP, Sanyou Medical has released a shareholder inquiry transfer plan, with the participating shareholder being QM5 LIMITED, intending to transfer a total of 6.66925 million shares, accounting for 2% of the company's total share capital

Sanyou Medical shareholders plan to inquire about the transfer of 2% of shares

Sanyou Medical announced that its joint venture Chuncheng Huayu's spinal surgery robot and related products have passed the special review process for innovative medical devices by the National Medical Products Administration and have been named the Spinal Surgery Navigation and Positioning System. This marks another important milestone for Sanyou Medical in innovative research and development. The approval of this product will accelerate its market launch and have a positive impact on the company's business

Sanyou Medical: Joint venture company products pass the special review procedure for innovative medical devices

Sanyou Medical announced that the actual controller and its concerted parties will reduce their holdings by 2.14 million shares through block trading from September 8 to September 12, 2025, bringing their shareholding ratio down to 27.80%. This reduction will not lead to a change in the actual controller and will not have a significant impact on the company's governance structure and future operations

Sanyou Medical: The shareholding ratio of the actual controller and its concerted actors has decreased to 27.80% after the change in equity

688236

01858

Zhongtai Securities released a research report stating that although short-term medical insurance cost control has a negative impact on the medical device industry, it remains optimistic about import substitution and global development driven by innovation. It is expected that the third quarter of 2025 will see a phased turning point for the medical device sector, especially with significant improvements in the high-value consumables segment after centralized procurement. The firm is optimistic about the competitiveness of domestic companies, breakthroughs in overseas markets, and investment opportunities in themes such as AI in healthcare

Chunli Medical

CHUNLI MEDICAL

Zhongtai Securities: High-value consumables are expected to be the first to emerge from policy disturbances, continuing to be optimistic about medical device innovation + going overseas

Sanyou Medical(688085.SH)